Comparison of sevelamer hydrochloride with colestimide, administered alone or in combination with calcium carbonate, in patients on hemodialysis

Therapeutic Apheresis and Dialysis

Volumn 12, Issue 2, 2008, Pages 126-132

  Itoh, Kazuko ^a   Tanaka, Motoko ^a   Hashiguchi, Junichiroh ^b   Funakoshi, Satoshi ^b   Nakano, Hirofumi ^c   Kubo, Hitoshi ^d   Kono, Takashi ^e   Uchino, Junji ^e   Masaki, Kazunobu ^f   Date, Toshiyuki ^g   Shigematsu, Takashi ^h  

^a Akebono Clinic   (Japan)

^b Sakuramachi Clinic   (Japan)

^c Dialysis Center   (Japan)

^d Aoto Kidney Clinic   (Japan)

^e Mihama Hospital   (Japan)

^f Shin Koiwa Clinic   (Japan)

^g Date Clinic   (Japan)

^h WAKAYAMA MEDICAL UNIVERSITY   (Japan)

Author keywords

Colestimide; Hyperphosphatemia; Sevelamer hydrochloride

Indexed keywords

ALKALINE PHOSPHATASE; CALCIUM; CALCIUM CARBONATE; COLESTILAN; PARATHYROID HORMONE; PHOSPHATE; SEVELAMER;

ABDOMINAL PAIN; ADULT; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; BLOATING; CALCIUM BLOOD LEVEL; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG WITHDRAWAL; FEMALE; GASTROINTESTINAL SYMPTOM; HEMODIALYSIS; HEMODIALYSIS PATIENT; HUMAN; HYPERPHOSPHATEMIA; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MORTALITY; MULTICENTER STUDY; NAUSEA; PARATHYROID HORMONE BLOOD LEVEL; PHOSPHATE BLOOD LEVEL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ADULT; AGED; CALCIUM; CALCIUM CARBONATE; CHELATING AGENTS; DRUG THERAPY, COMBINATION; EPICHLOROHYDRIN; FEMALE; HUMANS; HYPERPARATHYROIDISM, SECONDARY; HYPERPHOSPHATEMIA; IMIDAZOLES; JAPAN; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; PHOSPHORUS; POLYAMINES; PROSPECTIVE STUDIES; RENAL DIALYSIS; RESINS, SYNTHETIC;

EID: 41749083023     PISSN: 17449979     EISSN: 17449987     Source Type: Journal    
DOI: 10.1111/j.1744-9987.2008.00557.x     Document Type: Article

References (17)

1. Reslerova M, Moe SM. Vascular calcification in dialysis patients: pathogenesis and consequences. Am J Kidney Dis 2003 41 : S96 S99.
2. Block GA, Hulbert-Shearon TE, Levin NW, Port FK. Association of serum phosphorus and calcium × phosphate product with mortality risk in chronic hemodialysis patients: a national study. Am J Kidney Dis 1998 31 : 607 17.
3. Young EW, Albert JM, Satayathum S et al. Predictors and consequences of altered mineral metabolism: the Dialysis Outcomes and Practice Patterns Study. Kidney Int 2005 67 : 1179 87.
4. Block GA, Klassen PS, Lazarus JM, Ofsthum N, Lowrie EG, Chertow GM. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol 2004 15 : 2208 18.
5. Chertow GM, Dillon M, Burke SK et al. A randomized trial of sevelamer hydrochloride (RenaGel) with and without supplemental calcium: strategies for the control of hyperphosphatemia and hyperparathyroidism in hemodialysis patients. Clin Nephrol 1999 51 : 18 26.
6. Iwasaki Y, Takami H, Tani M et al. Efficacy of combined sevelamer HCl and calcium carbonate therapy for hyperphosphatemia in Japanese hemodialysis patients. Ther Apher Dial 2005 9 : 347 51.
7. Date T, Shigematsu T, Kawashita Y, Satake N, Morita K. Colestimide can be used as a phosphate binder to treat uraemia in end-stage renal disease patients. Nephrol Dial Transplant 2003 18 : iii90 3.
8. National Kidney Foundation. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 2003 42 : S1 201.
9. Japanese Society for Dialysis Therapy. Guidelines for the management of secondary hyperparathyroidism in chronic dialysis patients. J Jap Soc Dial Ther 2006 39 : 1435 55.
10. Chertow GM, Bruke SK, Raggi P. Treat to Goal Working Group. Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int 2002 62 : 245 52.
11. Katsumata K, Kusano K, Hirata M et al. Sevelamer hydrochloride prevents ectopic calcification and renal osteodystrophy in chronic renal failure rats. Kidney Int 2003 64 : 441 50.
12. Koiwa F, Onoda N, Kato H et al. Prospective randomized multicenter trial of sevelamer hydrochloride and calcium carbonate for the treatment of hyperphosphatemia in hemodialysis patients in Japan. Ther Apher Dial 2005 9 : 340 6.
13. Chertow GM, Burke SK, Dillon MA, Slatopolsky E. Long-term effects of sevelamer hydrochloride on the calcium × phosphate product and lipid profile of haemodialysis patients. Nephrol Dial Transplant 1999 14 : 2907 14.
14. Nagano N, Miyata S, Abe M, Wakita S, Kobayashi N, Wada M. Sevelamer hydrochloride reverses parathyroid gland enlargement via regression of cell hypertrophy but not apoptosis in rats with chronic renal insufficiency. Nephrol Dial Transplant 2005 21 : 634 43.
15. Almirall J, Lopez T, Vallve M, Ruiz A, Llibre J, Betriu A. Safety and efficacy of sevelamer in the treatment of uncontrolled hyperphosphataemia of haemodialysis patients. Nephron Clin Pract 2004 97 : c17 22.
16. Galassi A, Spiegel DM, Bellasi A, Block GA, Raggi P. Accelerated vascular calcification and relative hypoparathyroidism in incident haemodialysis diabetic patients receiving calcium binders. Nephrol Dial Transplant 2006 21 : 3215 22.
17. Block GA, Raggi P, Bellasi A, Kooienga L, Spiegel DM. Mortality effect of coronary calcification and phosphate binder choice in incident hemodialysis patients. Kidney Int 2007 71 : 438 41.